Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)

被引：36

作者：

Besse, B. ^{[1
,2
]}

Johnson, M. ^{[3
]}

Jaenne, P. A. ^{[4
]}

Garassino, M. ^{[5
]}

Eberhardt, W. E. E. ^{[6
,7
]}

Peters, S. ^{[8
]}

Toh, C. K. ^{[9
]}

Kurata, T. ^{[10
]}

Li, Z. ^{[11
]}

Kowanetz, M. ^{[11
]}

Mocci, S. ^{[11
]}

Sandler, A. ^{[11
]}

Rizvi, N. A. ^{[12
]}

机构：

[1] Gustave Roussy, Villejuif, France

[2] Univ Paris 11, Orsay, France

[3] Sarah Cannon Res Inst, Nashville, TN USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Fdn IRCCS Ist Nazl Tumori, Thorac Oncol Unit, Milan, Italy

[6] Univ Klinikum Essen, West German Canc Ctr, Essen, Germany

[7] Ruhrlandklin, Essen, Germany

[8] CHU Vaudois, Dept Oncol, Lausanne, Switzerland

[9] Natl Canc Ctr, Singapore, Singapore

[10] Kansai Med Univ, Hirakata Hosp, Osaka, Japan

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] Columbia Univ, New York, NY USA

来源：

关键词：

D O I：

10.1016/S0959-8049(16)31938-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

16LBA

引用

页码：S717 / S718

页数：2